Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Lumos Diagnostics has initiated a pivotal study in the U.S. to secure CLIA waiver status for its FebriDx test, which could significantly expand its market reach. Supported by BARDA’s funding, the study aims to improve antibiotic use by distinguishing bacterial infections, potentially unlocking a $1.7 billion market opportunity. Successful completion is anticipated by spring 2025, opening doors to a broader healthcare market.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
